Computational protein-misfolding drug platform Revenir for genetic obesity, Parkinson’s (GBA1), and Alpha-1 antitrypsin deficiency; CGX-926 dosed in Phase 1/1b for MC4R-deficient obesity; Ono Pharmaceutical collaborations
No detailed funding rounds available.
Total known funding: